Injectable semaglutide has a safety profile consistent with other GLP-1 drugs — mainly GI side effects — with cardiovascular benefits, though diabetic retinopathy risk warrants caution.
CV superiority confirmedSUSTAIN 6 trial showed semaglutide reduces cardiovascular events in type 2 diabetes
What the researchers found
Semaglutide demonstrated cardiovascular superiority in SUSTAIN 6, with a safety profile typical of GLP-1RAs. The only concerning signal was increased diabetic retinopathy events, likely related to rapid glucose lowering rather than direct drug toxicity.
Why it matters
Semaglutide has become one of the most widely prescribed diabetes medications. Understanding its full safety profile helps clinicians make informed prescribing decisions, especially for patients with existing eye complications.
The numbers in context
SUSTAIN 6 showed CV superiority; GI side effects most common; increased DR events; modest gallbladder signal; no confirmed MTC or pancreatitis risk
How the study worked
Comprehensive review of published safety data from the SUSTAIN Phase 3 clinical trial program and related literature on once-weekly GLP-1 receptor agonist safety.
Who was studied
Adults with type 2 diabetes across the treatment spectrum
What this study cannot tell us
Review of existing trial data — no new safety analysis. Long-term safety beyond trial durations not fully known at time of publication. Post-marketing real-world safety data was still accumulating.
How to read the evidence
Strong — based on multiple Phase 3 randomized controlled trials (SUSTAIN program) enrolling thousands of patients across the diabetes disease spectrum.
When this study was published
Published in 2020; since then, semaglutide has been approved for obesity (Wegovy) and substantial real-world safety data has accumulated.
The bigger picture
This safety review came at a pivotal time — semaglutide was expanding beyond diabetes into obesity treatment. Understanding its safety profile in diabetic populations helped inform risk-benefit discussions for broader use.
Questions still open
- Is the diabetic retinopathy signal due to rapid glucose lowering or a direct effect of semaglutide?
- How does the safety profile of oral semaglutide compare to the injectable form?
- What is the long-term gallbladder risk with sustained semaglutide use?
Common questions
What are the most common side effects of injectable semaglutide?
Should people with eye problems avoid semaglutide?
Read the original research
Safety of injectable semaglutide for type 2 diabetes.
Expert opinion on drug safety, 19(7), 785-798
Citation
Peter, Rajesh; Bain, Steve C. (2020). Safety of injectable semaglutide for type 2 diabetes.. Expert opinion on drug safety, 19(7), 785-798. https://doi.org/10.1080/14740338.2020.1772230